Mectizan Donation Program | Local power. Global Change.
MERCK A program at The Task Force for Global Health
Switch to French site

Mectizan Expert Committee Statement on Potential Efficacy of Ivermectin on COVID-19

A report by Caly et al found that ivermectin has shown in vitro activity against SARS-COV-2 (COVID-19) in tissue culture with Vero-hSLAM cells. These findings are consistent with the activity of ivermectin previously reported against other viruses in vitro. However, the high concentration of ivermectin needed to produce anti-viral effects in laboratory tissue culture is far beyond dosage levels approved by the FDA for treatment of parasites in humans and known to be safe and well tolerated. Furthermore, the concentration is many times higher than dosage levels ever tested in humans. High doses in animal models have produced serious toxicity. These preliminary laboratory findings in tissue cultures are not sufficient to indicate that ivermectin will be of clinical benefit to reduce viral loads in COVID-19 patients.

Caly, L., et al., The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral research, 2020.

News, videos & resources

Get the latest on the Mectizan Donation Program

News

Lymphatic Filariasis Eliminated in Malawi

28 October 2020

The World Health Organization (WHO) announced in this week’s WHO Weekly Epidemiological Record that Malawi has been validated to have eliminated lymphatic filariasis as a public health problem.

MDP/Merck Grant Application For Supplementary Funding for COVID-19 Mitigation

This is the Mectizan Donation Program and Merck & Co., Inc. grant application to assist non-governmental organization (NGO) partners with resuming mass drug administration by supporting implementation of COVID-19 mitigation strategies.

MDP/Merck Grant Application For Supplementary Funding for COVID-19 Mitigation (139.68 KB)

Annual Highlights

2019 Mectizan Donation Program Annual Highlights (English)

These are the accomplishments of the Mectizan Donation Program and its partners in 2019.

MDP Annual Highlights 2019 (English) (8.27 MB)

Annual Highlights

2019 Mectizan Donation Program Annual Highlights (French)

These are the accomplishments of the Mectizan Donation Program and its partners in 2019.

MDP Annual Highlights 2019 (French) (9.08 MB)

MDP Publication: Building country capacity to sustain NTD programs and progress: A call to action

This research article, co-authored by MDP’s Yao Sodahlon and Joni Lawrence, Merck’s Rachel Taylor, The Task Force for Global Health’s CEO, Dave Ross, and many NTD program managers, is focused on the need for building country capacity by increasing country ownership and domestic spending for NTD programs.

Sodahlon et al., 2020 (453.99 KB)
view more news & resources